Jana L. Gevertz

Model-supported patient stratification using multi-objective synergy optimization in combination therapy

This paper develops a method to stratify patients for combination therapy by optimizing synergy across efficacy and potency, using a preclinical mouse dataset to demonstrate subgroup-specific treatment responses.

Delaying Cancer Progression by Integrating Toxicity Constraints in a Model of Adaptive Therapy

This paper develops a mathematical model to assess how incorporating toxicity feedback affects adaptive cancer therapy, finding that toxicity-induced treatment breaks can extend time to progression.

Using Virtual Patients to Evaluate Dosing Strategies for Bispecifics with a Bell-Shaped Efficacy Curve

The paper develops a pharmacokinetic/pharmacodynamic model to evaluate dosing strategies for trimer-based bispecific antibodies, finding that the current recommended dose is optimal for a broad population and that patient stratification based on biomarkers can improve efficacy.

Understanding therapeutic tolerance through a mathematical model of drug-induced resistance

This paper develops a mathematical model of drug-induced resistance that fits experimental data and identifies optimal dosing strategies to minimize tumor cell volume.

Minimally Sufficient Experimental Design using Identifiability Analysis

The paper introduces a framework to determine the minimal experimental design needed for parameter identifiability in mathematical models, applied to a pharmacokinetic/pharmacodynamic model of drug distribution in the tumor microenvironment.